Boston Capital
Vertex can’t quell uncertainty
Vertex Pharmaceuticals Inc. should be on top of the world. It’s drug to treat hepatitis C - years in development - became a virtual blockbuster as soon as it went on sale this year. The Cambridge company is also developing promising therapies to treat other diseases. But Vertex shares are sinking like a rock, down more than 36 percent since mid-September. Investors worry a new generation of other hepatitis C treatments - still in development - will overtake Vertex.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Sign up
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
BostonGlobe.com subscriber
Click to continue reading this article or to log in to BostonGlobe.com.
